India's Zydus Life and Lupin fall on losing US patent case for bladder disorder drug

Astellas Pharma

16/04/2025 09:56

** India's Zydus Lifesciences ZYDU.NS and Lupin LUPN.NS shed 6.6% and 3.8%, respectively

** Drugmakers lose patent litigation case in US for mirabegron, a generic version of Astellas Pharma's 4503.T bladder disorder drug Myrbetriq

** ZYDU and LUPN top losers on pharma index .NIPHARM which is down 0.2%

** It is a negative development for Zydus and Lupin as loss in litigation implies that they have to withdraw the drug from the market and could see some financial penalty, says Equirus

** Brokerage estimates $35 mln in quarterly sales from mirabegron for ZYDU and $25-30 mln for LUPN

** YTD, ZYDU drops ~15% while LUPN falls ~18%; pharma index down 11%

 (Reporting by Kashish Tandon in Bengaluru)

 ((Kashish.tandon@thomsonreuters.com))